NTRK2

Biomarker

NTRK2 fusions are rare but actionable oncogenic drivers. Detection supports use of tumor-agnostic TRK inhibitors.

Approvals

Indications

Therapies

Mapped tests

Where this biomarker is used

Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.

Indication-specific approvals

Approvals where NTRK2 is defined directly in the indication labeling.

No indication-specific approvals are currently mapped for this biomarker.

Tumor-agnostic approvals

Approvals defined at the solid tumor level where NTRK2 is part of the eligibility criteria.

Level	Biomarker criteria	Therapies
Solid Tumors	fusions	VITRAKVI ROZLYTREK

Tests that measure this biomarker

These assays report NTRK2 as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.

Test

FoundationOne CDx

Foundation Medicine, Inc.

Method

NGS

Specimen

Tissue (FFPE)

Reports NTRK2 as part of its biomarker panel.

2 approvalsView test profile →

Test

FoundationOne Liquid CDx

Foundation Medicine, Inc.

Method

NGS

Specimen

Whole blood

Reports NTRK2 as part of its biomarker panel.

1 approvalView test profile →

Test

TruSight Oncology Comprehensive

Illumina, Inc.

Method

NGS

Specimen

Tissue (FFPE)

Reports NTRK2 as part of its biomarker panel.

1 approvalView test profile →

This view is scoped to NTRK2. You can also see how it compares with other biomarkers and indications on the Know Your Companions™ map.